Study of the gastric acid anti-secretory activity of Cannabis sativa in an animal model;Estudio de la actividad antisecretora de ácido gástrico del Cannabis sativa en un modelo animal

Colombia Medica

Volumn 37, Issue 4, 2006, Pages 254-257

  Castillo, Germán Gabriel ^a   Pachajoa, Harry Mauricio ^a   Villota, Sandra Eliana ^a   Zurita, Edwin ^a   Palacios, Mauricio ^a   Gutiérrez, Oscar ^a  

^a UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Cannabinoids; Cannabis; Gastric juice; Tetrahydrocannabinol

Indexed keywords

CANNABIS; GENFAR; RANITIDINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; GASTRECTOMY; LIGATION; MALE; NONHUMAN; PH MEASUREMENT; PYLORUS; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; STOMACH ACID SECRETION; STOMACH CONTENT; STOMACH PH; STOMACH VOLUME;

EID: 33845214968     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 (Suppl 1): 345-358.
2. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360.
3. Ashton CH. Pharmacology and effects of Cannabis: a brief review. Br J Psychiatry 2001; 178: 101-106.
4. Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta (9)-THC) on humans. Toxicon 2004; 44: 461-467.
5. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173: 2373-2382.
6. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6: 35-42.
7. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-178.
8. Kraft B, Kress HG. Cannabinoids and the immune system. Of men, mice and cells. Schmerz 2004; 18: 203-210,
9. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
10. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225: 1-8.
11. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384: 37-42.
12. Herkenham M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems.Ann NY Acad Sci 1992; 654: 19-32.
13. Noyes R Jr, Brunk, SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol 1975; 18: 84-89.
14. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, et al. Phamacokinetics and metabolism of tetrahydrocannabinol and other cannabionoids with emphasis on man. Pharmacol Rev 1986; 38: 21-43.
15. Christie MJ, Vaughan CW. Neurobiology cannabinoids act backwards. Nature 2001; 410: 527-530.
16. Galve-Roperh I, Sánchez C, Cortés ML, del Pulgar TG, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activatton. Nat Med 2000; 6: 313-319.
17. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut J 2001; 48: 859-867.
18. Izzo AA. Cannabinoids and intestinal motility: Welcome to CB2 receptors. Br J Pharmacol 2004; 142: 1201-1202.
19. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004; 142: 1247-1254.
20. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003; 12: 39-49.
21. Nalin DR, Levine MM, Rhead J, Bergquist E, Rennels M, Hughes T, et al. Cannabis, hypochlorhydria, and cholera. Lancet 1978; 2: 859-862.
22. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-esophageal reflux disease. Drugs 2004; 64: 277-295.
23. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001; 15: 355-370.